Work

Human vaccines & immunotherapeutics: News October 2023

Year: 2023

Type: article

Abstract: Bispecific immunotherapy improves long-term survival in metastatic melanomaFirst-line treatment with the bi-specific T-cell receptor tebentafusp (Immunocore) induced 3-year overall survival of 27% in HLA-A *02:01-positive patients with metastatic uveal melanoma, compared to 18% in a control group receiving standardof-care immunotherapy or chemotherapy.The Phase 3 KIMMTRAK trial also reported median overall survival of 22 and 17 months, respectively.1Tebentafusp is an engineered T-cell receptor targeting the gp100 antigen overexpressed in melanoma and the CD3 T-cell co-receptor.It is thus designed to engage both CD8 + and CD4 + T cells with the malignant cells.

Source: Human Vaccines & Immunotherapeutics

DOI: 10.1080/21645515.2023.2282040

Authors: Ronald Ellis, Adam Weiss

Institution: Taylor and Francis (United Kingdom)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,175